Abstract and Introduction
Introduction
On March 18, 2019, the Food and Drug Administration (FDA) extended approval for ceftazidime-avibactam to pediatric patients 3 months of age and older for the treatment of complicated intra-abdominal infections (cIAI) in combination with metronidazole and the treatment of complicated urinary tract infections (cUTI) including pyelonephritis.[1] Ceftazidime-avibactam was first approved in 2015 for adults with cIAI and cUTI, and was subsequently approved for the treatment of hospital-acquired or ventilator-associated pneumonia in February 2018.[2,3] A recent systematic review and meta-analysis confirmed its utility in cIAI and cUTI in adults, with results similar to those achieved with carbapenems in susceptible organisms, while offering an effective agent for patients with carbapenem-resistant Gram-negative infections.[4]
Pediatr Pharm. 2019;25(5) © 2019 University of Virginia
